Drug Database · Clinicians

Fluocinolone acetonide + Neomycin

Brands (2) Neo-Synalar 10, Neo-Synalar 25Show all

US brand (reference label): Neo-Synalar; not a Philippine-registered brand.

Corticosteroid (Corticosteroid Hormone Receptor Agonists) US FDA class
Anti-inflammatory/Antipruritic/Antibacterial; Corticosteroid/Antibiotic PH FDA category
Fixed-dose combination.

Rx · Prescription drug2 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 1141956e-8a4c-4f80-95d1-f15bdb57fdf6, version date March 18, 2026 (Neo-Synalar · Eurofarma, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE NEO-SYNALAR ® cream is indicated for the treatment of corticosteroid-responsive dermatoses with secondary infection.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE NEO-SYNALAR ® cream is indicated for the treatment of corticosteroid-responsive dermatoses with secondary infection. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see WARNINGS section).

Contraindications

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. This product should not be used in the external auditory canal if the eardrum is perforated.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION NEO-SYNALAR ® cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Since NEO-SYNALAR ® cream is a water-washable vanishing cream, it is easily applied and leaves no traces.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalmic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalmic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids.

Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen.

Chronic corticosteroid therapy may interfere with the growth and development of children.

Dosage forms

Philippines

  • Cream: 100 mcg/5 mg
  • Per g cream: 5 mg/250 mcg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Fluocinolone acetonide + Neomycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Fluocinolone acetonide + Neomycin
Package insert
Neo-Synalar 10Fluocinolone Acetonide/Neomycin Sulfate
100 mcg/5 mg (0.01% w/w/0.5% w/w) CreamAluminum Collapsible Tube x 5 g (box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Euro-Med Laboratories Phil., Inc.
DR-6978
Oct 11, 2037
Neo-Synalar 25Neomycin Sulfate + Fluocinolone Acetonide
5 mg/250 mcg per g (0.5% w/w / 0.025% w/w) CreamCollapsible Tube x 5 g (Box of 1's)
Rx
Interphil Laboratories Inc.Philippines
Trader: Euro-Med Laboratories Phil., Inc.
DR-X6330
May 19, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS If local infection should continue or become severe, or in the presence of systemic infection, appropriate systemic antibacterial therapy, based on susceptibility testing, should be considered. Because of the concern of nephrotoxicity and ototoxicity associated with neomycin, this combination product should not be used over a wide area or for extended periods of time. There are articles in the current medical literature that indicate an increase in the prevalence of persons sensitive to neomycin.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria The following adverse reactions have been reported with the topical use of neomycin: Ototoxicity Nephrotoxicity

Adverse reaction frequency tables (US label) US FDA label
BurningHypertrichosisMaceration of the skin
ItchingAcneiform eruptionsSecondary infection
IrritationHypopigmentationSkin atrophy
DrynessPerioral dermatitisStriae
FolliculitisAllergic contact dermatitisMiliaria
OtotoxicityNephrotoxicity

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Pharmacokinetics (US label) US FDA label

Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Neo-Synalar · Eurofarma, Inc. [US FDA-approved label, version 5, March 18, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1141956e-8a4c-4f80-95d1-f15bdb57fdf6
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .